Bivalirudin versus heparin in contemporary percutaneous coronary interventions for patients with acute coronary syndrome: a systematic review and meta-analysis
CONCLUSIONS: These findings suggest that bivalirudin use during PCI reduced the risk of NACE and all-cause death but did not reduce the risk of MACE compared with heparin use in PCI. More studies specifically designed for anticoagulation strategies and a personalized anticoagulation regimen to comprehensively balance bleeding and ischemia risks are required.PMID:37964648 | DOI:10.5603/cj.90956
Source: Cardiology Journal - Category: Cardiology Authors: Junyan Zhang Zhongxiu Chen Duolao Wang Chen Li Fangbo Luo Yong He Source Type: research
More News: Angiomax | Angioplasty | Bleeding | Cardiology | Clopidogrel | Coronary Angioplasty | Databases & Libraries | Heart | Percutaneous Coronary Intervention | Plavix | Study